CompletedNCT00246285
Six months of risperidone treatment for adolescents with schizophrenia
About this title
A Study of the Effectiveness and Safety of Risperidone in the Treatment of Adolescents With Schizophrenia
Read the official source — NCT00246285This study evaluated the safety and effectiveness of risperidone for people with schizophrenia.
Medication studyAges 13–17
Understand this study
What did researchers investigate?
This study evaluated the safety and effectiveness of risperidone for people with schizophrenia.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 13 years to 17 years. Other eligibility criteria applied.
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateApril 2001
- Recruitment status
- Completed
- Enrollment listed in the registry
- 381
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Not clearly listed
- Age range
- From 13 Years to 17 Years
- Official registry ID
- NCT00246285
- Official title
Show the full official title
The Efficacy And Safety Of Risperidone In The Treatment Of Adolescents With Schizophrenia: A Six-Month Open-Label Study.
Get this study by email
Recruitment & locations
CompletedLocations not listed
Questions about this study
What did researchers investigate?
This study evaluated the safety and effectiveness of risperidone for people with schizophrenia.
Who is behind this study?
The study sponsor is Johnson & Johnson Pharmaceutical Research & Development, L.L.C., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including risperidone.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 13 years to 17 years. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
Paliperidone Injections Compared With Oral Medication for Schizophrenia
18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia